In type 1 diabetes mellitus (type 1 DM), an eating disorder (ED) may occur, referred to as «diabulimia,» in which patients use insulin to control body weight, contributing to the decompensation of endocrinopathy. In the presented clinical case, a patient (35 years old) with a 10-year history of type 1 diabetes mellitus intentionally refuses regular insulin administration in order to reduce body weight. The psychopathological qualification of the phenomenon underlying the ED presented as diabulimia in this patient corresponds to grandiose notions as part of schizotypal disorder (F21). The peculiarity of the condition in this clinical case is that the grandiose notion of weight loss was observed before the manifestation of type 1 diabetes mellitus, and later, it was included in the structure of the internal presentation of the disease (endocrinopathy), led to manipulations with insulin therapy, which in turn resulted in late complications of diabetes.
6 October 2025 in S.S. Korsakov Journal of Neurology and Psychiatry
Semaglutide is a glucagon-like peptide-1 receptor agonist, approved and currently actively used worldwide for the treatment of type 2 diabetes mellitus and obesity. With the growing popularity of the drug, reports of both adverse and beneficial effects of the drug on mental health have become more frequent. The purpose of this study is to review the impact of semaglutide on mental health by collecting, analyzing, and synthesizing current scientific evidence. The authors conclude that currently there is no unequivocal opinion on this matter, which opens up new horizons for future research.